Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.55 |
| ▸ | HTR2A | P28223 | 8/20 | 0.55 |
| ▸ | KMO | O15229 | 2/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7676168 | 1.00 | HTR2C (0.55) | HTR2CHTR2AKMOPRMT5HTR7 | |
| SCHEMBL8959778 | 0.87 | HTR2C (0.72) | HTR2CHTR2APRMT5CYP1A2CYP3A4 | |
| SCHEMBL8959781 | 0.87 | HTR2C (0.72) | HTR2CHTR2APRMT5CYP1A2CYP3A4 | |
| SCHEMBL24144837 | 0.87 | HTR2C (0.58) | HTR2CHTR2AKMOPRMT5HTR7 | |
| SCHEMBL7997689 | 0.84 | HTR2C (0.77) | HTR2CHTR2AKMOPRMT5HTR7 | |
| SCHEMBL8959657 | 0.82 | HTR2C (0.71) | HTR2CHTR2APRMT5HTR7CYP1A2 | |
| SCHEMBL8959650 | 0.82 | HTR2C (0.71) | HTR2CHTR2APRMT5HTR7CYP1A2 | |
| SCHEMBL7253587 | 0.81 | HTR2C (0.55) | HTR2CHTR2APRMT5HTR7 | |
| SCHEMBL7253595 | 0.81 | HTR2C (0.55) | HTR2CHTR2APRMT5HTR7 | |
| SCHEMBL8959921 | 0.81 | HTR2C (0.72) | HTR2CHTR2APRMT5HTR7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380238-B1 | FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-30 | — | — | US | disclosed |